within Pharmacolibrary.Drugs.G_GenitoUrinarySystemAndSexHormones.G03G_GonadotropinsAndOtherOvulationStimulants.G03GA04_Urofollitropin;

model Urofollitropin
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_1C(
    weight = 70,
    F = 1,
    Cl = 1.3888888888888888e-07,
    adminDuration = 600,
    adminMass = 225 / 1000000,
    adminCount = 1,
    Vd = 0.0087,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Urofollitropin</td></tr><tr><td>ATC code:</td><td>G03GA04</td></tr><td>route:</td><td>subcutaneous</td></tr>
    <tr><td>compartments:</td><td>1</td></tr>
    <tr><td>dosage:</td><td>225</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>8.7</td><td>L</td></tr>
    <tr><td>clearance:</td><td>0.5</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Urofollitropin is a purified form of the follicle-stimulating hormone (FSH) derived from the urine of postmenopausal women. It is used in the treatment of infertility in women, particularly in assisted reproductive technologies such as in vitro fertilization (IVF), to stimulate the development of multiple follicles. The drug is approved and widely used in fertility treatments.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy female volunteers following subcutaneous administration.</p><h4>References</h4><ol></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.G.G03GA04 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Urofollitropin;
